Last reviewed · How we verify
Glucose-Insulin-Potassium
Glucose-Insulin-Potassium is a Metabolic support therapy Small molecule drug developed by Centre Hospitalier Universitaire Vaudois. It is currently in Phase 3 development for Acute myocardial infarction, Cardiac protection during ischemic events. Also known as: GIK.
Glucose-Insulin-Potassium (GIK) therapy delivers glucose, insulin, and potassium together to improve myocardial metabolism and reduce ischemic injury during acute cardiac events.
Glucose-Insulin-Potassium (GIK) therapy delivers glucose, insulin, and potassium together to improve myocardial metabolism and reduce ischemic injury during acute cardiac events. Used for Acute myocardial infarction, Cardiac protection during ischemic events.
At a glance
| Generic name | Glucose-Insulin-Potassium |
|---|---|
| Also known as | GIK |
| Sponsor | Centre Hospitalier Universitaire Vaudois |
| Drug class | Metabolic support therapy |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The GIK regimen enhances cardiac energy metabolism by promoting glucose uptake and utilization in ischemic myocardium while the potassium component helps maintain cellular electrolyte balance and reduce arrhythmias. This metabolic support reduces infarct size and improves cardiac function recovery in the setting of acute myocardial infarction or cardiac stress.
Approved indications
- Acute myocardial infarction
- Cardiac protection during ischemic events
Common side effects
- Hyperglycemia
- Hypokalemia
- Fluid overload
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Prevention and Treatment of Common Hyperglycemia in Surgery Pilot (PHASE4)
- Maple Syrup Carbohydrate Dose-Response on 20-km Cycling Time-Trial Performance (NA)
- Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health (NA)
- Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke (PHASE1)
- Recovery After Dialysis-Requiring Acute Kidney Injury (NA)
- MAGIK for Femoral/Tibial Shaft Fractures (PHASE2)
- Lower Vs. Standard Insulin-Dextrose Doses for Treating Mild to Moderate Hyperkalemia in the Emergency Department (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glucose-Insulin-Potassium CI brief — competitive landscape report
- Glucose-Insulin-Potassium updates RSS · CI watch RSS
- Centre Hospitalier Universitaire Vaudois portfolio CI
Frequently asked questions about Glucose-Insulin-Potassium
What is Glucose-Insulin-Potassium?
How does Glucose-Insulin-Potassium work?
What is Glucose-Insulin-Potassium used for?
Who makes Glucose-Insulin-Potassium?
Is Glucose-Insulin-Potassium also known as anything else?
What drug class is Glucose-Insulin-Potassium in?
What development phase is Glucose-Insulin-Potassium in?
What are the side effects of Glucose-Insulin-Potassium?
Related
- Drug class: All Metabolic support therapy drugs
- Manufacturer: Centre Hospitalier Universitaire Vaudois — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute myocardial infarction
- Indication: Drugs for Cardiac protection during ischemic events
- Also known as: GIK
- Compare: Glucose-Insulin-Potassium vs similar drugs
- Pricing: Glucose-Insulin-Potassium cost, discount & access